1-10 of 10
Athos Gianella-Borradori
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT111: Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors

Howard Safran, Mihaela Druta, Michael Morse, Filipa Lynce, Sofya Pintova, Khaldoun Almhanna, Daniel Weiss, Athos Gianella-Borradori, Yoshitaka Ogita, Roland Morley, Mikiko Nakamura, Junnosuke Matsushima, Takahiro Ishiguro
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT111.
https://doi.org/10.1158/1538-7445.AM2021-CT111
Published: 01 July 2021
View article titled, Abstract CT111: Results of a phase 1 dose escalation study of ERY974, an anti-glypican 3 (GPC3)/CD3 bispecific antibody, in patients with advanced solid tumors
Journal Articles

Abstract 3028: PET imaging with the bispecific 89Zr-antibody ERY974 targeting CD3 and glypican 3 in tumor-bearing mouse models

Stijn J. Waaijer, Danique Giesen, Takahiro Ishiguro, Yuji Sano, Norihisa Ohishi, Athos Gianella-Borradori, Carolien P. Schröder, Elisabeth G. de Vries, Marjolijn N. Lub-de Hooge
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3028.
https://doi.org/10.1158/1538-7445.AM2018-3028
Published: 01 July 2018
View article titled, Abstract 3028: PET imaging with the bispecific <sup>89</sup>Zr-antibody ERY974 targeting CD3 and glypican 3 in tumor-bearing mouse models
Journal Articles

Abstract 2754: Phase I and pharmacokinetic (PK) study of two regimens combining the aurora kinase inhibitor AS703569 and gemcitabine in patients with advanced solid tumors

Ahmad Awada, Jerome Alexandre, Athos Gianella-Borradori, Sandrine Faivre, Blandine Longerey, Annick Seithel, Lucia Trandafir, Eric Raymond
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 2754.
https://doi.org/10.1158/1538-7445.AM10-2754
Published: 15 April 2010
View article titled, Abstract 2754: Phase I and pharmacokinetic (PK) study of two regimens combining the aurora kinase inhibitor AS703569 and gemcitabine in patients with advanced solid tumors
Journal Articles

Abstract 4433: A Phase I study of two dosing regimens of oral AS703569, an inhibitor of aurora kinase and other kinases, in patients with hematologic malignancies

Carlos Graux, Anne Sonet, Johan Maertens, Justus Duyster, Jochen Greiner, Yves Chalandon, Giovanni Martinelli, Dagmar Hess, Dominik Heim, Frank J. Giles, Athos Gianella-Borradori, Blandine Longerey, Narmyn Rejeb, Oliver G. Ottmann
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 4433.
https://doi.org/10.1158/1538-7445.AM10-4433
Published: 15 April 2010
View article titled, Abstract 4433: A Phase I study of two dosing regimens of oral AS703569, an inhibitor of aurora kinase and other kinases, in patients with hematologic malignancies
Journal Articles

Preclinical evaluation of the orally available Aurora kinase inhibitor AS703569 to support the selection of tumor indications for clinical studies

Armin Maier, Julia Schuler, Niko Bausch, Heinz Fiebig, Angela Romanelli, Athos Gianella-Borradori
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3264.
Published: 01 May 2007
View article titled, Preclinical evaluation of the orally available Aurora kinase inhibitor AS703569 to support the selection of tumor indications for clinical studies
Journal Articles

Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor

Ida Iurisci, Elisabeth Filipski, Jens Reinhardt, Stéphane Bach, Athos Gianella-Borradori, Stefano Iacobelli, Laurent Meijer, Francis Lévi
Journal: Cancer Research
Cancer Res (2006) 66 (22): 10720–10728.
https://doi.org/10.1158/0008-5472.CAN-06-2086
Published: 15 November 2006
View article titled, Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor
Open the PDF for Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor in another window
Journal Articles

Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1

David E. MacCallum, Jean Melville, Sheelagh Frame, Kathryn Watt, Sian Anderson, Athos Gianella-Borradori, David P. Lane, Simon R. Green
Journal: Cancer Research
Cancer Res (2005) 65 (12): 5399–5407.
https://doi.org/10.1158/0008-5472.CAN-05-0233
Published: 15 June 2005
View article titled, Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1
Open the PDF for Seliciclib (CYC202, R-Roscovitine) Induces Cell Death in Multiple Myeloma Cells by Inhibition of RNA Polymerase II–Dependent Transcription and Down-regulation of Mcl-1 in another window
Journal Articles

Identification and clinical validation of biomarkers to support the development of Seliciclib (CYC202).

Sheelagh Frame, Sian Anderson, Kathryn Watt, Ian N. Fleming, David E. Maccallum, Jean Melville, Morag Watson, Athos Gianella-Borradori, Simon R. Green
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 107.
Published: 01 May 2005
View article titled, Identification and clinical validation of biomarkers to support the development of Seliciclib (CYC202).
Journal Articles

CYC202 (R-Roscovitine) induces apoptosis in multiple myeloma cells by down regulation of Mcl-1

David E. Maccallum, Jean Melville, Kathryn Watt, Sian Anderson, Sheelagh Frame, Athos Gianella-Borradori, David P. Lane, Simon R. Green
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 189–190.
Published: 01 April 2004
View article titled, CYC202 (R-Roscovitine) induces apoptosis in multiple myeloma cells by down regulation of Mcl-1
Journal Articles

Identification of pharmacodynamic biomarkers for CYC202 (R-roscovitine), a cyclin dependent kinase inhibitor.

Simon R. Green, Sheelagh Frame, Kathryn Watt, Sian Anderson, Ian N. Fleming, David E. Maccallum, Jean Melville, Louise Neuwirth, Athos Gianella-Borradori, David P. Lane
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 846.
Published: 01 April 2004
View article titled, Identification of pharmacodynamic biomarkers for CYC202 (R-roscovitine), a cyclin dependent kinase inhibitor.